Instrument Inactif

Autres langues STALLERGENES

Actions

FR0000065674

Recherche biotechnologique et médicale

Cours en clôture Euronext Paris Autres places de cotation
- ^EUR	-

30/03/17	Stallergenes Greer : des objectifs rassurants.
30/03/17	Les valeurs à suivre aujourd'hui à la Bourse de Paris - Jeudi 30 mars 2017

Autres langues

22/02/16	STALLERGENES : GREER ANNOUNCES ITS 2016 FINANCIAL CALENDAR
10/02/16	STALLERGENES : MICHELE ANTONELLI APPOINTED PRESIDENT OF STALLERGENES SAS & EXECUTIVE VP HEAD OF EUROPE & ROW
10/02/16	STALLERGENES : MICHELE ANTONELLI APPOINTED PRESIDENT OF STALLERGENES SAS AND EXECUTIVE VP, HEAD OF EUROPE & REST OF WORLD
10/02/16	STALLERGENES : MICHELE ANTONELLI APPOINTED PRESIDENT OF STALLERGENES SAS AND EXECUTIVE VICE PRESIDENT, HEAD OF EUROPE & REST OF WORLD
01/02/16	STALLERGENES : GREER ANNOUNCES RESUMPTION OF MANUFACTURING AT ITS ANTONY PLANT
01/02/16	STALLERGENES : TIBOR NEMES APPOINTED GLOBAL HEAD OF TECHNICAL OPERATIONS
07/12/15	STALLERGENES : RECALL OF ALLERGY IMMUNOTHERAPY PRODUCTS
19/11/15	STALLERGENES : ANNOUNCES THE LAUNCH OF ACTAIR® IN JAPAN
10/11/15	STALLERGENES : Michele Antonelli appointed as Executive Vice President, Head of International Operations
10/11/15	STALLERGENES : Introducing a new global allergy company
10/11/15	STALLERGENES : Ares Allergy Holdings plc becomes Stallergenes Greer plc
10/11/15	STALLERGENES : Development of our House Dust Mite sublingual immunotherapy tablet
08/06/15	Stallergenes : is pleased to see the mobile allergen exposure chamber at the 2015 EAACI congress, Barcelona
24/10/14	Stallergenes : continues its international expansion with the opening of an affiliate in Canada.
23/10/14	Stallergenes : sales reach €45.7 million in Q3 2014; Oralair® achieves market leadership in France; Continued expansion of international markets (up 33%)
22/10/14	DBV TECHNOLOGIES : French developer of 'peanut allergy patch' makes U.S. debut
24/07/14	STALLERGENES : Half-year revenues and results
08/07/14	Stallergenes : welcomes Fleur Pellerin, Secretary of State for Foreign Trade to its principal site in Antony, Hauts-de-Seine, France.
06/06/14	Stallergenes : to be present at the 3rd annual Citi European healthcare conference on June 20, 2014
08/05/14	STALLERGENES : Industrial consortium announces its support for GA²LEN’s developement of mobile environmental exposure chambers
02/04/14	Stallergenes : announes FDA approval of Oralair®, the first sublingual immunotherapy tablet for the treatment of grass pollen allergy
03/02/14	STALLERGENES : reports positive results in the phase II/III clinical trial of house dust mite immunotherapy tablets in Japan
03/12/13	STALLERGENES : and ActoGeniX to develop together an innovative new class of oral treatments for allergy
25/07/13	STALLERGENES : Half-Year Revenues and Results
16/05/13	STALLERGENES : and DBV Technologies Enter into Partnership for the Development of Innovative Treatment of Respiratory Allergies